Wakasaki, T.; Yasumatsu, R.; Masuda, M.; Takeuchi, T.; Manako, T.; Matsuo, M.; Jiromaru, R.; Uchi, R.; Komune, N.; Noda, T.;
et al. Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Cancers 2020, 12, 2299.
https://doi.org/10.3390/cancers12082299
AMA Style
Wakasaki T, Yasumatsu R, Masuda M, Takeuchi T, Manako T, Matsuo M, Jiromaru R, Uchi R, Komune N, Noda T,
et al. Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Cancers. 2020; 12(8):2299.
https://doi.org/10.3390/cancers12082299
Chicago/Turabian Style
Wakasaki, Takahiro, Ryuji Yasumatsu, Muneyuki Masuda, Toranoshin Takeuchi, Tomomi Manako, Mioko Matsuo, Rina Jiromaru, Ryutaro Uchi, Noritaka Komune, Teppei Noda,
and et al. 2020. "Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma" Cancers 12, no. 8: 2299.
https://doi.org/10.3390/cancers12082299
APA Style
Wakasaki, T., Yasumatsu, R., Masuda, M., Takeuchi, T., Manako, T., Matsuo, M., Jiromaru, R., Uchi, R., Komune, N., Noda, T., & Nakagawa, T.
(2020). Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Cancers, 12(8), 2299.
https://doi.org/10.3390/cancers12082299